Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD is likely to experience significant growth in the near future due to their innovative telehealth platform, which includes key capabilities like a nationwide pharmacy network and AI-enabled technologies. This, along with their recent collaboration with AT&T and launch of a new FDA-approved product, is expected to drive revenue and profits. Risks to their expected growth include competition and potential dilution, but overall, LifeMD is well-positioned to capitalize on the growing demand for telehealth services and direct-to-consumer healthcare options.

Bears say

LifeMD is a high-growth, direct-to-consumer healthcare company that has seen recent success with telehealth and partnerships with insurance companies. However, their transition away from compounded GLP-1 medications has negatively affected short-term profitability. While long-term prospects are positive with the potential for Medicare growth and new partnerships, it may take time for the company to fully reap the benefits of its investments.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.